Eggshell Membrane Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Eggshell Membrane Market Trends and Insights

Osteoarthritis Burden Fuels Structural Demand for Joint Supplements

The global osteoarthritis burden, driven by aging populations and obesity-related joint stress, is significantly boosting the eggshell membrane market. In 2024, 607 million people globally were affected by osteoarthritis, with prevalence rates projected to rise by 2050. East Asia, where knee osteoarthritis accounts for 73% of cases, represents a key growth region. Middle-income economies expanding access to non-pharmacological joint support present strong near-term opportunities.^{[1]Lichun Qiao et al., “Epidemiological Trends of Osteoarthritis at the Global, Regional, and National Levels from 1990 to 2021 and Projections to 2050,” Arthritis Research & Therapy, doi.org} The NEM brand eggshell membrane differentiates itself by reducing the cartilage degradation biomarker CTX-II by 19.2% within a week, outperforming slower-acting alternatives like glucosamine and chondroitin.

Clean-Label and Upcycled Ingredient Demand Reframes Competitive Positioning

The eggshell membrane market benefits from its alignment with clean-label trends and the appeal of upcycled ingredients. Eggshell membrane, sourced from industrial egg-breaking streams, supports sustainability by diverting billions of eggshells from landfills annually. Over 800 products have achieved Upcycled Certified status, reflecting mainstream acceptance of this model. Suppliers emphasizing environmental performance gain an edge with multinational brands focused on ESG compliance. Eggnovo SL’s negative carbon footprint further strengthens the eggshell membrane’s premium positioning over lower-cost substitutes like bovine collagen and glucosamine.

Nutricosmetics and Beauty-from-Within Uptake Extends the Addressable Market

The eggshell membrane market is expanding into beauty-from-within products, supported by clinical evidence of its efficacy. A 12-week trial demonstrated significant improvements in skin metrics, including elasticity and wrinkle reduction, with measurable results by week six. The ingredient’s low effective dosage of 300–600 mg/day, compared to 5,000–15,000 mg/day for collagen peptides, enables its use in convenient formats like gummies and softgels. In Japan, Almado Co., Ltd. launched CELLULA FALCO Active Supplement in October 2024, targeting sleep quality, skin aging, and muscle mass retention, showcasing the ingredient’s multifunctional potential.

Regulatory Approvals for Food-Supplement Use Unlock New Geographies

Regulatory approvals are driving growth in the eggshell membrane market by enabling new product launches. In July 2024, Biova LLC’s water-soluble eggshell membrane received EU Novel Foods approval, granting five years of exclusivity in the premium supplement market. In December 2025, EFSA confirmed the safety of egg membrane collagen peptides for adult supplements at up to 500 mg/day without requiring toxicological studies. These approvals reflect a mature regulatory stance, positioning compliant suppliers to secure early market entry before competition intensifies.

Egg-Processing Dependence and Avian Disease Volatility

The eggshell membrane market faces supply challenges as raw membrane availability depends on industrial egg-breaking operations. In Q1 2025, nearly 40 million poultry were lost to avian influenza in the U.S., with recovery expected to take 9 months to a year if outbreaks remain contained. Since eggshell membrane is a byproduct, reduced egg-processing throughput lowers availability and increases fixed costs per unit. Cost pressures intensify when egg prices fluctuate, as seen with a spike to USD 8/dozen in February 2025 before dropping to USD 3/dozen in March. European suppliers, like Eggnovo SL, are investing in process improvements, but the market is likely to face sustained cost challenges in the near term.

Extraction Cost and Bioactive Standardization Burden

The eggshell membrane market is transitioning toward standardized, clinically validated ingredients, increasing production complexity. Research shows that room-temperature storage of membranes for 13 days degrades proteins, while same-day processing retains higher bioactivity. Clinical trials highlight the commercial importance of freshness, with same-day processed ingredients showing significantly better results. Additionally, producing 1 gram of pure collagen requires nearly 10 grams of raw membrane, depending on efficiency. Vertically integrated suppliers with traceability and cold-chain systems are better positioned, but the lack of universal standards slows adoption by brands needing FDA and EFSA-compliant documentation.

Segment Analysis

By Type: Unhydrolyzed Formats Gain Ground in Skin Applications

In 2025, hydrolyzed eggshell membrane held 67.40% of the market, driven by its established role in joint health nutraceuticals. Its market leadership is supported by extensive clinical validation, such as ESM Technologies’ NEM, which has been studied in over 10 human clinical trials for joint comfort and flexibility. While hydrolyzed formats remain central to revenue, unhydrolyzed eggshell membrane is forecast to grow at a 10.24% CAGR from 2026 to 2031, fueled by its increasing use in skin and beauty applications. Stratum Nutrition’s Ovolux, launched in 2025, demonstrated significant improvements in skin elasticity and firmness, highlighting the growing segmentation between hydrolyzed forms for joint support and unhydrolyzed forms for beauty products. Denk Ingredients’ expanded ESM® range reflects how suppliers are diversifying portfolios to capture both market segments.

By Product Form: Powder’s Versatility Supports Both Scale and Premiumization

Powder accounted for 31.55% of the market in 2025 and is projected to grow at a 10.76% CAGR from 2026 to 2031. Its versatility allows integration into capsules, sachets, gummies, functional foods, liquid shots, and effervescent formats, making it a preferred choice for formulators. Capsules and tablets remain relevant for joint health, while liquid and dispersible formats are gaining traction by addressing solubility challenges. Innovations like Eggnovo SL’s soluble vial format and Biova’s water-soluble BiovaFlex highlight the market’s shift toward enhanced delivery systems, premium pricing, and broader channel compatibility.

By Application: Cosmetics and Personal Care Accelerates While Nutraceuticals Hold the Revenue Base

Nutraceuticals and dietary supplements led the market with a 44.25% share in 2025, supported by clinical evidence and a strong history in joint health. Pharmaceutical applications are gaining relevance due to the eggshell membrane’s anti-inflammatory properties, while food and beverage applications face limitations from allergen labeling. Animal nutrition is growing, with clinical trials showing significant benefits in pet supplements. Cosmetics and personal care are the fastest-growing segment, projected to expand at an 11.67% CAGR from 2026 to 2031. Products like Sirio Pharma and Eggnovo SL’s HydraPearls Glow are positioning eggshell membrane alongside premium beauty products, broadening its appeal while maintaining its clinical credibility.

Geography Analysis

In 2025, North America led the eggshell membrane market with a 37.65% share. The region's mature supplement retail system, strong acceptance of clinically-claimed products, and the presence of key domestic suppliers like ESM Technologies, Biova LLC, and Stratum Nutrition drive its dominance. These factors enable faster commercialization, supported by established connections between ingredient developers, product brands, and retail channels.

Europe is the second-largest market for eggshell membranes, with growth previously constrained by regulatory delays rather than demand. Biova's EU Novel Foods approval in July 2024 allowed European brands to use U.S.-sourced eggshell membranes with fewer regulatory barriers. Additionally, investments like Eggnovo SL's factory upgrades for processing enhance local supply resilience, positioning Europe for balanced growth in demand and supply.

Asia-Pacific is projected to grow at a CAGR of 11.45% from 2026 to 2031, making it the fastest-growing region in the eggshell membrane market. Japan leads with a mature market supported by product recognition and research collaborations. South Korea's high osteoarthritis incidence and China's rising burden create significant opportunities, while India's FSSAI approval for NEM facilitates premium joint supplement launches. The Middle East, Africa, and South America remain smaller markets but show potential due to improving retail systems and growth in Brazil's nutraceutical sector.